Cuál es el precio por Entropy Neurodynamics Limited (ENP)

Precio por Entropy Neurodynamics Limited (ENP) es de$0.02468497

Cuál es la capitalización de mercado por Entropy Neurodynamics Limited (ENP)

Capitalización de mercado por Entropy Neurodynamics Limited (ENP) es $40.28M

Entropy Neurodynamics Limited (ENP) Desdoblamientos de Acciones

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.